GRI Bio, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-13 | -3.74 | -1.61 | +56.95% |
| 2026-01-30 | -29.26 | -116.61 | -298.53% |
| 2025-11-14 | -31.08 | -35.84 | -15.32% |
| 2025-08-14 | -36.68 | -36.68 | — |
| 2025-05-15 | -105.98 | -162.40 | -53.24% |
| 2024-11-14 | -347.48 | -318.92 | +8.22% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| GRI | -5.50% | -9.65% | -70.21% | -94.55% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -8.47% | -5.01% | -66.77% | -107.24% |